๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Electrophysiologic evaluation of antiarrhythmic drugs

โœ Scribed by Paul Touboul


Publisher
Springer US
Year
1990
Tongue
English
Weight
365 KB
Volume
4
Category
Article
ISSN
0920-3206

No coin nor oath required. For personal study only.

โœฆ Synopsis


Electrophysiologic techniques are used to assess the properties of antiarrhythmic drugs and also to provide support for the selection of antiarrhythmic therapy for individual patients. Assessment of the antiarrhythmic efficacy of drugs requires that the arrhythmia can be induced by programmed electrical stimulation and is critically dependent on the stimulation protocol. Continued inducibility on drug therapy appears to be a strong predictor of recurrences and sudden death, although the predictive value of electrophysiologic testing remains controversial for some drugs. These techniques may also be useful for determining the proarrhythmic potential of antiarrhythmic agents, but the aggravation of tachycardia that occurs in 10-30% of patients during electrophysiologic testing is unpredictable and its significance is unknown. The electrophysiologic approach to drug therapy has limitations, but, nevertheless, it is useful and should maintain a prominent place in the evaluation of antiarrhythmic therapy.


๐Ÿ“œ SIMILAR VOLUMES


Antiarrhythmic and electrophysiologic ef
โœ Lewis V. Buchanan; Dwayne D. Thompson; Chang-Yuan L. Hsu; Rodney R. Walters; Joh ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 573 KB

lbutilide fumarate is a class Ill antiarrhythmic agent in phase Ill clinical trials. Due to rapid hepatic metabolism, ibutilide has a low oral bioavailability (< 10%). To assess alternate routes of administration, we performed repeated studies of the electrophysiologic effects of sublingual ibutilid

Comparative hemodynamics of antiarrhythm
โœ Magdi Sami ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 369 KB

It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myoca